Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients

Inclusion Criteria: * Transplant-eligible newly diagnosed multiple myeloma based on current IMWG criteria and scheduled for induction chemotherapy followed by ASCT. Remark: patiënts can also be included after ASCT, prior to maintenance therapy, if a baseline FDG-PET CT scan showing FDG avid disease is available. * Baseline 18F-FDG PET/WBLDCT scan should be performed before start of treatment (preferably) or within 7 days after start of treatment. Scan must show FDG avid disease (=at least 1 FL ≥ DS3 and/or diffuse bone marrow involvement). * WHO performance status 0-2 (WHO \> 2 can be allowed if due to underlying disease and after discussion with the physician). * Age ≥ 18 years * Life expectancy \> 12 months, based on clinical judgement. Eligibility criteria for the primary endpoint * achieving at least a VGPR after induction chemotherapy and ASCT according to the standard IMWG response criteria. * received at least one (28-day) cycle of lenalidomide as maintenance therapy after ASCT. No new therapy can be given until clinical relapse. Exclusion Criteria: * Any physical or physiological condition that may affect adherence to the study protocol, e.g. severe claustrophobia or the inability to lie still for 30 minutes. * uncontrolled diabetes * History of concomitant presence of any other malignancy, except for: * non-melanoma skin cancer * carinoma in situ of the cervix * any other effectively treated malignancy that has been in remission for \> 5 years or that is highly likely to be cured at the time of enrollment. * pregnant or breastfeeding * refusal or inability to provide written informed consent